CASE CCC IN THE NEWS
UH Rainbow Launches NE Ohio's Only Phase 1 Clinical Trials Program for Young Cancer Patients
The Plain Dealer - Feb 6, 2014
Earlier this year UH Rainbow – the pediatric affiliate of the Case Comprehensive Cancer Center at Case Western Reserve University – became the first hospital in Northeast Ohio to make Phase 1 trials available for pediatric cancer patients. The first study to open is testing a new combination of drugs in up to 30 patients with relapsed leukemia or lymphoma...By the end of February, two other Phase 1 trials will be ready to enroll patients. Dr. Robin Norris, a pediatric oncologist at UH, is the national primary investigator for one of the trials, testing the safety of a new drug for patients whose cancer (solid tumor) has returned...Another UH Rainbow oncologist, Dr. Alex Huang, had received funding from the foundation and had also organized a team to raise money for the foundation's Million Mile Run in 2013.
Cleveland Doctors Studying Stem Cells with Success (video)
Fox 8 - Feb 5, 2014
Case Comprehensive Cancer Center members Drs. Jeremy Rich and David Wald discuss cell-based therapies conducted through the National Center for Regenerative Medicine.
Early Promise for a Blood Thinner Without the Bleeding Risk
US News & World Report - Feb 5, 2014
An experimental drug appears to prevent dangerous blood clots, without raising the risk of excessive bleeding – at least in animals..."The holy grail in this field is to be able to give something that prevents clots, without causing bleeding," said Dr. Alvin Schmaier, a professor at Case Western Reserve University in Cleveland, who wrote an editorial published with the study.
VeloSano Cycling Event Registration Now Open
Westlake Bay Village Observer - Feb 4, 2014
Registration for VeloSano, the annual cycling event to raise money for cancer research at Cleveland Clinic, is now open to the public. Cyclists can choose either a one- or two-day cycling experience...and 100 percent of funds raised by participants will directly benefits cancer research at Cleveland Clinic..."Funds raised by VeloSano and its riders will help our physicians and researchers generate discoveries and explore novel therapies for treating cancer," said Brian J. Bolwell, M.D., FACP, chairman of Cleveland Clinic's Taussig Cancer Institute. "We encourage all Northeast Ohioans to join the movement and consider participating in the event as a cyclist or a volunteer."
New Agent Misses the Mark in Advanced Prostate Cancer
Medscape - Feb 4, 2014
A promising investigational agent for metastatic castration-resistant prostate cancer has failed to meet its primary end point in a phase 3 trial. There was no significant improvement in overall survival when orteronel (Takeda) was added to prednisone. Median overall survival with orteronel plus prednisone was similar to that with placebo plus prednisone. The study was terminated for failing to meet its primary end point. However, orteronel –did lead to a notable improvement in radiographic progression-free survival,– reported lead author Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, and chair of the Department of Solid Tumor Oncology at the Cleveland Clinic Foundation.
Transforming Oncology Care With PET/MR
Imaging Technology News - Feb 3, 2014
By Pablo Ros, MD, PhD, MPH. Following commercial availability of the Philips Ingenuity TF PET/MR in late 2011, University Hospitals Seidman Cancer Center continues to see the benefits of this hybrid modality.
Maintenance Chemo Delays Progression in Metastatic CRC
Medscape - Jan 27, 2014
Maintenance treatment with capecitabine ( Xeloda) and bevacizumab ( Avastin) significantly delayed disease progression, compared with observation, in patients with metastatic colorectal cancer. There was also a trend toward improved overall survival, although this did not reach statistical significance, according to final results from the CAIRO3 trial, which were presented here at the 2014 Gastrointestinal Cancers Symposium...Study discussant Neal J. Meropol, MD, from the University Hospitals Seidman Cancer Center and Case Western Reserve University in Cleveland, noted that the CAIRO3 findings show that it is "feasible yet challenging to conduct a window-of-opportunity study after induction therapy."
CTSC Core Utilization Pilot Award Recipients
Congratulations to the recipients of the November 2013Clinical and Translational Science Collaborative (CTSC)Core Utilization Pilot Awards:
- Marvin Nieman, PhD: Analysis of the Phosphoproteome in Thrombin Stimulated Platelets
- Zhenghe John Wang, PhD: Targeting Glutamine Metabolism for Cancer Therapy
Disease Team sign-off and PRMC protocol submission
Effective immediately, the Protocol Review and Monitoring Committee (PRMC) will not be accepting protocol submissions without Disease Team sign-offs from both institutions. One of the functions of the Case CCC Clinical Trials Disease Teams is to "recommend action to PRMC for trial advocacy and priority" by providing "pre-review by experts in their field for scientific merit, prioritization, and intent to accrue patients" (Case CCC Clinical Trials Operations Manual). Disease Team sign-off from both hospitals has been a longstanding requirement and protocol submissions will no longer be accepted by PRMC without it. Please note that the overall responsibility of following-up and obtaining sign-offs rests with the PI and the study team. Contact April Firstencel, PRMC Manager, at 216.286.2294 or firstname.lastname@example.org any questions.
Vote for Dr. Stan Gerson for the AACR Nominating Committee
Last chance to vote for Dr. Stan Gerson, who is on the ballot for the American Association for Cancer Research (AACR) Nominating Committee. The election will close this Friday, February 14. Voting instructions will be distributed to all voting members of AACR. Election results will be announced in March 2014 and elected candidates will assume office at the AACR Annual Meeting 2014 in April.
Please show your support for Dr. Gerson and vote for him! It would be great to have local votes that place our director on the Nominating Committee, which selects candidates for major awards, the annual meeting program committee, and the slate of candidates for national positions.
CORE FACILITY SPOTLIGHT
Imaging Research Core Facilitates Research Using Bioluminescent Imaging Technology
When Dr. Bill Schiemann and his lab needed to conduct research using Bioluminescent Imaging technology to investigate breast cancer metastasis in a single animal, they tapped into the resources available through the Imaging Research Core, led by Dr. Chris Flask. Together, the investigators produced a video publication, In vivo Dual Substrate Bioluminescent Imaging, in the "Journal of Visualized Experiments (JoVE)", a PubMed-indexed video journal. The publication demonstrated how to construct, visualize, and quantify the bioluminescent reactions of both firefly and renilla luciferase enzymes expressed in metastatic breast cancer cells during their growth and metastasis in vivo.
The Imaging Research Core provides access to in vivo preclinical imaging techniques including Magnetic Resonance Imaging, XRay, CT, and PET. More advanced, specialized imaging techniques can also be obtained through collaboration with one of 25 imaging research faculty in the Core and the Case Center for Imaging Research (CCIR).
"The expertise of the Case Comprehensive Cancer Center Imaging Core provided us with a unique and powerful opportunity to not only image breast tumor development and metastasis in real-time in mice, but also to simultaneously visualize the flux through oncogenic signaling systems that mediate these deadly events," said Dr. Schiemann. "More importantly, these innovative imaging systems also provided us with novel insights into how alterations with the tumor microenvironment or the administration of breast cancer chemotherapies impact oncogenic signaling systems during breast cancer metastasis and disease recurrence."
SAVE THE DATE
Team Science Workshop
On Monday, February 17 the Clinical and Translational Science Collaborative (CTSC) will host a Team Science Workshop from 1-4 pm in the Wolstein Research Building Auditorium. This workshop is a forum to enhance our understanding of Team Science and how it can advance research efforts through collaboration. Team Science is a collaborative and multidisciplinary research effort that joins together researchers to explore a specific research problem with specific targeted goals. Team Science collaborations can join together individuals from the same department, other institutions, community organizations, and/or other organizations that typically do not interact with one another. Teams can vary in focus from training, clinical translation, public health issues, and scientific discovery.
The National Institutes of Health has been explicit in its support of Scientists working in teams to solve complex problems. The National Center for the Advancement of Translational Sciences promotes this model. The partner institutions will demonstrate their support of a team science environment by enhancing the infrastructure through pilot funding, technology transfer resources and support, and other shared resources.
Inaugural Case Comprehensive Cancer Center Academic Drug Development Seminar
The Inaugural Case Comprehensive Cancer Center Academic Drug Development Seminar, will be held on February 26 at 4pm in the Global Cardiovascular Innovation Center, 10000 Cedar Avenue. This first seminar will feature a presentation by Dr. Goutham Narla, Assistant Professor, Medicine and Transformative Molecular Medicine at CWRU/UH, on Drugging the Undruggable: Small Molecule Activators of Tumor Suppressor Genes.
As part of the Case CCC Developmental Therapeutics Program, this series will gather clinicians, scientists, medical chemists, computer-aided drug designers, screeners, and commercialization personnel in the same room as a stimulating presentation so that all attendees can learn and benefit from the sparked interaction. More details will be circulated in the near future, but please save the date and plan to attend this event. Free parking is available.
Retreat: Engaging in Cultural Competence through Awareness, Knowledge and Action
Please mark your calendars for Thursday, March 13 from 2-5 pm to join the Case Comprehensive Cancer Center and the Case Center for Reducing Health Disparities as they explore issues related to cultural competence. Extend your knowledge and raise your awareness about the dynamic variety of people and communities the Case CCC serves. This retreat will feature a keynote address by Dr. Sonja Harris-Haywood, and will provide perspective on the growing need to be culturally competent and facilitate the impact of cultural beliefs within the health care setting, specifically in research.
The retreat is intended for investigators, research nurses, regulatory coordinators, outreach and training and education personnel. Pre-registration is required. Please direct any questions to Katarzyna Karelus at 216.844.4176 or email@example.com.
Screening for Cancer in Women: 2014
Please mark your calendars and plan to attend Screening for Cancer in Women: 2014, on Wednesday, May 21 from 8 am - 3 pm at the Embassy Suites Hotel in Independence.
Optimal strategies in cancer screening and detection are constantly evolving and best practices are changing.
This update is aimed at primary care providers and cancer specialists with guides that can be incorporated into their practices:
- New screening technologies, particularly to detect breast and lung cancer
- Current guidelines for colorectal, skin, lung, breast, and cervical cancer screening
- Impact of the Affordable Care Act and racial and economic disparities on cancer detection
- When to refer a patient for a genetics referral or to a high-risk clinic
CME credit will be offered. Pre-registration is required. Check the Cancer Center website for more information.
Case GI SPORE Request for Project Proposals
All Faculty members are invited to submit Concept Proposals for consideration to be incorporated as full projects in the Case GI SPORE P50 award. All proposals must be directed towards translational research of a GI malignancy, with at least one specific aim that involves direct study of patients or of human tissues. Opportunities will include:
- the possibility of current inclusion and funding as a full Project in the currently funded GI SPORE;
- opportunities for start-up support from the GI SPORE pilot project program commencing Sept. 2014;
- opportunities for inclusion as a full project proposed in the SPORE competing renewal proposal that will be prepared starting in January 2015 for submission in September 2015.
Deadline: February 15
Brian Werbel Memorial Fund
Applications are currently being accepted for summer cancer research fellowship funding, provided by the Brian Werbel Memorial Fund. This fund was established in 2007 at University Hospitals Case Medical Center, and is dedicated to providing summer fellows an opportunity to focus on cancer research, with the ultimate goal to aid in curing cancer. Brian's hope was to find a cure for cancer – to make a difference in the world, just as he made a difference in the lives of everyone he touched. Applicants must be conducting cancer research with a Case Comprehensive Cancer Center member. Awardees are required to attend the Annual Golf Outing Event, typically held in July.
Deadline: April 25